Trial Profile
Open, Non Controlled, Parallel Cohorts, Multicenter, Phase 2A Study for Evaluation of the Antitumor Activity of GM102 Single Agent and in Combination With Chemotherapy in Patients With Locally Advanced Or Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Murlentamab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors GamaMabs Pharma
- 11 Apr 2022 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: Cohort II expansion: GM102 + trifluridine/tipiracil arm.
- 11 Apr 2022 Status changed from active, no longer recruiting to completed.
- 29 Apr 2021 This trial has been completed (Global End Date: 10 Feb 2021), according to European Clinical Trials Database record.